SPE Capital

SPE Capital operates with a senior team that the firm describes as having nearly 100 years of combined experience, but the firm does not publicly name individual investment-committee members or a chief investment officer. Decision-making appears to sit with the senior partners, who work from offices in Tunis, Abidjan, Cairo, Casablanca and Paris. Investors seeking clarity on governance should request the firm's committee structure during due diligence.

The firm attributes its pipeline to a multi-local presence — investment professionals are stationed in five offices who maintain long-term relationships with business owners, local intermediaries and development-finance networks. This on-the-ground model is designed to surface proprietary opportunities that pan-regional funds managed remotely might miss. The firm also co-invests alongside DFIs such as EBRD and Proparco, which provide additional origination channels in emerging and frontier markets.

SPE Capital primarily executes direct and co-investment transactions in growth-equity, buyout, turnaround and restructuring situations. The available public record shows no evidence of the firm acting as a fund-of-funds or making LP commitments into external vehicles. Its capital is deployed predominantly into portfolio companies alongside co-investors from the development-finance community.

The firm states it focuses on sectors where it has significant resources, experience and expertise, naming healthcare as one confirmed vertical through its March 2025 investment in an ophthalmic pharmaceutical manufacturer. SPE Capital also published research on artificial-intelligence applications in emerging-market private equity in October 2025, suggesting a growing capability in technology-enabled businesses. Beyond these signals, precise sector concentration is not publicly disclosed.

In March 2026, Amethis succeeded SPE Capital as the majority shareholder in ADEMAT, indicating a completed exit transaction. The announcement confirmed a clean transfer of control, though financial terms were not disclosed. This exit demonstrates the firm's ability to manage full-cycle investments and transition portfolio companies to next-stage owners, a critical competency for institutional allocators evaluating a manager's realized track record.

SPE Capital actively co-invests alongside development-finance institutions and other strategic partners, as shown by the March 2025 ophthalmic pharmaceutical deal syndicated with EBRD, Proparco and BIO. The firm does not appear to market a formal co-investment club or offer side-by-side participation rights to external limited partners, but its deal history shows comfort operating within consortium structures.

The firm's investor base consists of more than 20 limited partners — primarily leading development-finance institutions, family offices and high-net-worth individuals, according to the firm's own disclosures. SPE Capital does not identify a single wealth-generating source, founder family or sovereign patron. This LP composition suggests a diversified, non-captive capital base aligned with the firm's multi-local investment mandate.